Ute Klaassen, MD

Articles

Paclitaxel and UFT Plus Oral Calcium Folinate in Pretreated Metastatic Breast Cancer

Ute Klaassen, MD;David Borquez, MD;Stephanie Lang, MD;Carsten Oberhoff, MD;Andreas Harstrick, MD;Siegfried Seeber, MD, PhD;Steven Benner, MD

July 1st 1999

This phase I study was designed to determine the maximum tolerated dose (MTD) and dose-limiting side effects of combination treatment with paclitaxel (Taxol) and UFT (uracil and tegafur in a 4:1 molar ratio) plus oral

Fluorouracil-Based Combinations in the Treatment of Metastatic Breast Cancer

Ute Klaassen, MD;Hans Jochen Wilke, MD

January 1st 1998

Although combination chemotherapy regimens may prolong survival for selected patients with metastatic breast cancer, few, if any, are cured. The standard regimens used in treatment, eg, CMF (cyclophosphamide,

Metastatic Breast Cancer: Treatment With Fluorouracil-Based Combinations

Ute Klaassen, MD;Siegfried Seeber, MD, PhD

September 2nd 1997

During the 1990s, one in nine women in the western world will be diagnosed with breast cancer, and more than 58,000 will die of the disease each year in Europe alone. Recent changes in the primary therapy of operable

Infusional 5-FU, Folinic Acid, Paclitaxel, and Cisplatin for Metastatic

Ute Klaassen, MD;Hans Jochen Wilke, MD;Christian Müller, MD;David Borquez, MD;Michael Korn, MD;Klaus Diergarten, MD;Siegfried Seeber, MD, PhD

April 1st 1997

Our phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose, 24-hour infusional 5-fluorouracil(5-FU)/folinic acid (HD5-FU/FA) in intensively pretreated patients with metastatic